UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2025 001-39218 CONMED CORPORATION (Exact name of the registrant as specified in its charter) Delaware 16-0977505 (State or other jurisdiction of incorporation or organization) (I ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

For the quarter ended September 2025, Conmed (CNMD) reported revenue of $337.93 million, up 6.7% over the same period last year. EPS came in at $1.08, compared to $1.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $336.52 million, representing a surprise of +0.42%. The company delivered an EPS surprise of +2.86%, with the consensus EPS estimate being $1.05.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

Conmed (CNMD) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.86%. A quarter ago, it was expected that this medical technology company would post earnings of $1.13 per share when it actually produced earnings of $1.15, delivering a surprise of +1.77%.Over the last four quarters, th ...

CONMED (NYSE:CNMD) Q3 2025 Earnings Call November 05, 2025 04:30 PM ET Speaker1Good day and thank you for standing by. Welcome to ConMed's third quarter fiscal 2025 earnings conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, ...

Investor Presentation Q3 2025 Earnings Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer November 5, 2025 Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward- looking statements herein or in previous disclosures ...

CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2025 Financial Results Largo, Florida, November 5, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights NEWS RELEASE "We are pleased with our third quarter performance, which reflects continued progress in strengthening our supply chain and strong execution across our core growth p ...

We came across a bullish thesis on CONMED Corporation on DeepValue Capital’s Substack. In this article, we will summarize the bulls’ thesis on CNMD. CONMED Corporation's share was trading at $46.00 as of September 26th. CNMD’s trailing P/E was 12.99 according to Yahoo Finance. 10 Most Competitive Medical Fellowships in America egyjanek/Shutterstock.com Conmed Corporation (CONMED) is a global medical device company focused on enabling less invasive and more effective surgery across orthopedics, general s ...

Zacks Premium服务概述 - 提供Zacks Rank和Zacks Industry Rank每日更新服务 帮助投资者提升投资决策能力 [1] - 包含Zacks第一排名清单全访问权限 股票筛选工具及股票研究报告资源 [1] - 整合Zacks风格评分系统作为核心分析工具 [1] Zacks风格评分系统构成 - 采用字母评级体系（A至F级）评估股票价值 增长和动量三大投资特性 [3] - 价值评分侧重市盈率 PEG比率 市销率及现金流倍数等估值指标 [3] - 增长评分关注企业财务健康度 历史及预测收益 销售额与现金流表现 [4] - 动量评分分析股价趋势 周度价格变化及盈利预期月度百分比调整 [5] - VGM评分综合三大风格评分 通过加权计算筛选兼具价值 增长与动量优势的股票 [6] 评分系统与Zacks排名协同机制 - Zacks排名依托盈利预测修正模型 1988年以来第一评级股票年均回报率达+23.75% [7] - 每日超200家公司获强力买入评级 另有600家维持买入评级 [8] - 建议优先选择Zacks排名第1-2级且风格评分达A-B级的股票 [9] - 即使风格评分优异 第4-5级评级股票因盈利预期下行仍存在股价下跌风险 [10] 案例企业Conmed(CNMD)分析 - 公司主营微创手术器械及监测设备制造 拥有3600名员工及多处生产基地 [11] - 当前Zacks排名为持有级 VGM风格评分获A级 [11] - 动量评分达B级 近四周股价上涨8.6% [12] - 过去60天内两名分析师上调2025财年盈利预测 共识预期上调0.04美元至每股4.46美元 [12] - 历史平均盈利惊喜度达+9.2% 兼具优势排名与评分特征 [12]

Zacks研究服务核心功能 - 提供Zacks评级和行业排名每日更新 Zacks第一评级名单 股票研究报告及高级选股工具 [1] - 包含Zacks风格评分系统作为核心分析工具 帮助投资者构建高胜率投资组合 [1][2] 风格评分系统构成 - 价值评分通过市盈率 PEG 市销率等比率识别被低估股票 [3] - 增长评分分析预测和历史收益 销售额及现金流寻找可持续增长标的 [4] - 动量评分利用周价格变动和月度盈利预期变化判断交易时机 [5] - VGM综合评分整合三大风格因子 采用加权计算方式 [6] 评分与评级协同机制 - Zacks评级基于盈利预期修正模型 第一评级股票自1988年来年均回报达23.75% [7] - 每日有超过200只强买入评级股票及600只买入评级股票 [8] - 建议优先选择同时具备第一/二评级和A/B风格评分的股票 [9] - 即使获得A/B评分 若评级为卖出/强卖出仍存在股价下跌风险 [10] 医疗器械公司Conmed案例 - 公司主营微创手术器械及监测设备 拥有3600名员工及多个生产基地 [11] - 当前获Zacks持有评级 VGM评分达到A级 [11] - 过去四周股价上涨4.8% 动量评分获A级 [12] - 60天内两名分析师上调2025财年盈利预期 共识预期上调0.04美元至每股4.46美元 [12] - 历史平均盈利惊喜度达+9.2% 兼具优质评级与高分风格评分 [12]